--- a
+++ b/clusters/9knumclustersv2/clust_1535.txt
@@ -0,0 +1,120 @@
+Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication (napabucasin or FOLFIRI) within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-), where a minimum of  days since last dose must be observed prior to the first planned dose of study medication. Standard dose of bevacizumab ( mg/kg) may be administered prior to FOLFIRI infusion, per Investigator decision, for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization. Radiotherapy, immunotherapy (including immunotherapy administered for non-malignant diseaseneoplastic treatment purposes), or investigational agents within four weeks of first planned dose of study medication, with the exception of a single dose of radiation up to  Gy (equal to  RAD) with palliative intent for pain control up to  days before randomization.
+Prior therapy\r\n* Patients =<  days from the last dose of cytarabine used for treatment of TMD
+All Cohort A Dose Escalation Participants:\r\n* Prior hormonal therapy: Participants may have received any number of previous endocrine / hormonal lines of therapy in the metastatic setting (including prior fulvestrant), as long as the last dose is >=  days prior to first dose of study treatment\r\n* Prior biologics / investigational therapy: Prior therapy with biologics and investigational drugs is allowed, as long as the last dose is >=  days prior to first dose of study treatment\r\n* Prior CDK/ inhibition is allowed; participants who have had prior ribociclib must have received treatment at full-dose without any dose reductions; the last dose is required to be >=  days prior to first dose of study treatment\r\n* Treatment with prior PD/PDL/CTLA inhibitors is prohibited\r\n* Prior radiotherapy: Participants may have received radiotherapy for palliative purposes but must have completed treatment ?  days prior to first dose of study treatment and not be experiencing grade >  treatment-related toxicities\r\n* Evaluable or measurable disease by RECIST .
+Cohort B Safety Run-In (Ribociclib + PDR + Fulvestrant): Prior CDK/ inhibition is allowed; participants who have had prior ribociclib must have received treatment at full-dose without any dose-reductions; the last dose is required to be >=  days prior to first study treatment
+Expansion Cohort B (Ribociclib + PDR + Fulvestrant): Prior chemotherapy:\r\n* Participants may have received up to one prior line of chemotherapy for advanced breast cancer as long as the last dose is >=  days prior to first dose of study treatment
+Any chemotherapy within the  days prior to the first dose of study drug.
+Tamoxifen and aromatase inhibitors within  days prior to the first dose of study drug.
+Fulvestrant within  days prior to first dose of study drug.
+Immunomodulating agents < days prior to first dose of study drug
+Treatment with antibiotics within  days prior to first dose of study drug.
+Neurological stability for at least  days prior to first dose of study drug;
+Patients must not have received any vaccines for  days prior to administration of their first dose of MT- and should not receive any vaccine during the study or within  days after their last dose of MT-.
+Female subjects who are breastfeeding, or intend to breastfeed during the duration of the study and for  days following the last dose of study drug.
+Patients who have had chemotherapy within  weeks prior to first dose of study drug.
+CLL therapy, with the exception of ibrutinib within the following timeframes:\r\n* Chemotherapy, external beam radiation therapy, anticancer antibodies within  days prior to the first dose of drug on this study\r\n* Corticosteroid use >= mg prednisone within  week prior to first dose on this study\r\n* Radio- or toxin-conjugated antibody therapy within  weeks prior to first dose on this study\r\n* Allogeneic stem cell transplant within  months prior to first dose on this study
+Received hydroxyurea therapy within  days ( weeks) before the first dose of any study drug
+Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:
+The most recent dose of olaratumab must have been received within  days of randomization in this study.
+Non-oncology vaccines within  days prior to or after any dose of ipilimumab
+Subject has no significant worsening in clinical status for a minimum of  days prior to first dose of study drug.
+Participants must have discontinued EGFR targeted therapy prior to the first dose of study drug.
+The following restrictions apply to current or prior anti-cancer treatment, prior to the first dose of study drug:\r\n* Patients who are actively receiving any other investigational agents\r\n* Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within  weeks prior to the first dose of study drug\r\n* Radio- or toxin-immunoconjugates within  weeks prior to the first dose of study drug\r\n* Previous treatment with greater than one of the study agents (i.e., venetoclax, ibrutinib, obinutuzumab or Revlimid), excluding prior prednisone or rituximab treatment\r\n* Prior allogeneic stem cell (or other organ) transplant within  months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within  days prior to first dose of study drug\r\n* Not recovered (i.e., =< grade  or baseline) from adverse events due to previously administered anti-cancer treatment, surgery, or procedure; NOTE: exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)
+Within  days of the first dose of study drug: Platelets >= ,/L
+Anti-cancer therapy less than  days prior to the first dose of study drug (less than  days for bevacizumab) or palliative, focal radiation therapy less than  days prior to the first dose of study drug
+Cytotoxic chemotherapy last dose must have been received at least  days prior to enrollment, their last dose of biological therapy, immunomodulatory agents, vaccines, differentiating agents, used to treat their cancer at least  days prior to enrollment, their last dose of a monoclonal antibody at least  days prior to enrollment, and their last dose of any investigational agent at least  days prior to enrollment
+Patients previously treated with regorafenib, lonsurf or capecitabine as the last prior regimen can start on this study as long as there is at least  week of period between the last dose of previous treatment and day  in this study provided the patients are eligible; patients who were on FOLFOX or FOLFIRI regimens must have at least  weeks period between the last dose and the first dose in this clinical study; patients previously treated with Avastin, Zaltrap, cetuximab, pembrolizumab, panitumumab, nivolumab Erbitux, and Vectibix must have at least  weeks period between the last dose of previous chemotherapy and the first dose in this clinical study
+Anti-cancer therapy less than  weeks prior to the first dose of study drug (less than  days for bevacizumab) or palliative, focal radiation therapy less than  days prior to the first dose of study drug
+Prior chemotherapy or radiotherapy within  days prior to first dose of therapy provided subject has received no growth factor support of any kind within  days prior to first dose of therapy, otherwise prior chemotherapy within  days prior to first dose of therapy
+Anti-cancer therapy less than  days prior to the first dose of study drug or palliative, focal radiation therapy less than  days prior to the first dose of study drug
+Patients who have received systemic corticosteroids within  days prior to the first dose of study drug
+Patients who have received systemic nonsteroidal antiinflammatory drug (NSAID) therapy within  days prior to the first dose of study drug
+Prior somatostatin analogue therapy; (patients should receive the first dose of study drug no sooner than  weeks from the last dose of somatostatin analogue)
+Major surgeries (eg, abdominal laparotomy) within  weeks of the first dose of study drug. Following major surgeries, > weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.
+Has completed prior therapies according to the criteria below:\r\n* Cytotoxic chemotherapy - at least  days since last dose prior to first dose of ribociclib\r\n* Small molecule inhibitors - at least  days since last dose prior to first dose of ribociclib\r\n* Monoclonal antibodies - at least  half-lives since last dose prior to first dose of ribociclib; exception: denosumab for bony metastases is allowable\r\n* Immunotherapy (e.g. tumor vaccines) - at least  days since last dose prior to first dose of ribociclib\r\n* Radiation - at least  days since last dose prior to first dose of ribociclib
+Radiation therapy within  days of the first dose of study drug
+Recent prior therapy, defined as . Any non-monoclonal anti-cancer therapy within  days or  half-lives, whichever is longer, prior to the first dose of GSK. Any nitrosoureas or mitomycin C within  days prior to the first dose of GSK. Prior therapy with biologic agents (including monoclonal antibodies) is permitted so long as  days have elapsed since therapy and all therapy-related AEs have resolved to =< Grade , . Any radiotherapy within  days or major surgery within  days prior to the first dose of GSK. For subjects in the GBM cohort, subjects must have completed radiation therapy at least  days prior to the first dose of GSK. . Anti-androgen therapies for prostate cancer, such as bicalutamide, must be stopped  weeks prior to enrollment. Second-line hormone therapies such as enzalutamide or abiraterone should be stopped  weeks prior to enrolment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone [up to  milligram (mg)/day] and still be eligible for this study.
+Subjects who have had radiation therapy within  week prior to first dose of drug
+Use of amiodarone within  days prior to first dose
+PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: A baseline brain MRI must be obtained no more than  days (+  working days) prior to study enrollment; the patient must either be on no steroids or a stable dose of dexamethasone no greater than  mg a day for at least  days prior to entrance onto the study
+PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: A baseline brain MRI obtained no more than  days (+  working days) prior to study enrollment on a stable dose of steroids no greater than  mg a day of dexamethasone for at least  days, is required prior to entrance of a patient onto the study; patients must be registered on the study within  weeks of completion of concurrent chemoradiation
+Use of amiodarone within  days prior to first dose
+For subjects on corticosteroids, they must be on a stable dose for  days prior to anticipated start of study drug
+Radiotherapy (RT) (At least  days from last local site RT prior to first dose of tazemetostat/At least  days from stereostatic radiosurgery prior to first dose of tazemetostat/At least  weeks from craniospinal, ?% radiation of pelvis, or total body irradiation prior to first dose of tazemetostat)
+Participants who have received any of the following prior to the first dose of study drug:
+If receiving eltrombopag or romiplostim, the dose must have been stable for ?  days prior to the first dose of PRTX-
+If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or -mercaptopurine, the dose must have been stable for ?  days prior to the first dose of PRTX- and must be expected to remain stable through study Day , unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- .
+Less than or equal to (</=)  hours between onset of ILI and first dose of study drug
+Previous enrollment on another study involving the investigation of veliparib (ABT-), with the exception of receiving a single dose of study drug
+Systemic anti-myeloma therapy within < days, or plasmapheresis within  days prior to the first dose of study drug.
+Patients must be  days to  weeks out from prior therapy:\r\n* Chemotherapy cytotoxic: At least  days since last dose of chemotherapy prior to first dose of tazemetostat\r\n* Chemotherapy nitrosoureas: At least  weeks since last dose of chemotherapy prior to first dose of tazemetostat\r\n* Chemotherapy non-cytotoxic (e.g. small molecule inhibitor): At least  days or five half-lives, whichever is shorter, since last dose of chemotherapy prior to first dose of tazemetostat\r\n* Monoclonal antibody(ies): At least  days since last dose of chemotherapy prior to first dose of tazemetostat\r\n* Immunotherapy: At least  days since last dose of chemotherapy prior to first dose of tazemetostat\r\n* Radiotherapy (RT): At least  days from last local site RT prior to first dose of tazemetostat\r\n* At least  days from stereotactic radiosurgery prior to first dose of tazemetostat\r\n* At least  days from craniospinal, > % radiation of pelvis or total body irradiation prior to first dose of tazemetostat
+Within  days of first dose of study drug: Platelets >  x ^/L
+Patient has any of the following within  days prior to the first dose of study drug:
+TREATMENT: Breastfeeding should be discontinued while the patient is on this trial and for  days following last dose of study drug
+Patients enrolled to the prior treatment arm of the dose escalation cohort must not have received anti-cancer therapy less than  days prior to the first dose of study drug or palliative, focal radiation therapy less than  days prior to the first dose of study drug
+Stable systemic cGVHD medication regimen for seven days prior to study enrollment; dose modifications to maintain therapeutic drug levels of immunosuppressants (i.e. tacrolimus and sirolimus) for the month prior and during the study intervention period are allowed and do not constitute a trial violation
+Ability to be off prednisone and other immunosuppressive drugs for at least  days before first dose of study drug
+Radiotherapy (RT) (At least  days from last local site RT prior to first dose of tazemetostat/At least  days from stereotactic radiosurgery prior to first dose of tazemetostat/At least  weeks from craniospinal, ? % radiation of pelvis, or total body irradiation prior to first dose of tazemetostat)
+Immunostimulants within  weeks or immunosuppressants within  days prior to study drug
+Anti-cancer therapy less than  days prior to the first dose of study drug or palliative, focal radiation therapy less than  days prior to the first dose of study drug.
+Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:
+Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than  weeks (or  half-lives of the drug, whichever occurs later) prior to first dose of study drug. Cessation of small molecule tyrosine kinase inhibitors must be at least  days prior to first dose of study drug.
+Agreement to use contraception during the study and for  days after the last dose of ACP- or  days after the last dose of pembrolizumab, if sexually active and able to bear or beget children.
+Time required between the last dose of the latest therapy and the first dose of study drug:
+Use of any of the following within  days prior to the first dose of IP:
+Contraception is recommended for  days prior to starting therapy, while participating in this study, during dose interruptions, and for at least  days after discontinuation of ibrutinib,  days after discontinuation of lenalidomide, and  months after discontinuation of rituximab
+Pleurodesis within  days prior to first dose of study drug
+Agreement to use highly effective forms of contraception during the study and for  days after the last dose of ACP ,  days after the last dose of bendamustine, or  months after the last dose of rituximab, whichever is longest.
+Any chemotherapy less than  days before first dose of study
+Currently receiving or has received any intensive chemotherapy within the  days prior to the first dose of study drug (day -) (Hydrea or other non-intensive regimens such as decitabine may be used but must stop at least one day prior to the first dose of study drug)
+Acceptable laboratory assessment obtained within  days prior to the first dose of study drug:
+Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within  weeks of the first dose of study drug; received thoracic radiation therapy of > Gy within  months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within  days of the first dose of study drug
+The first dose of atezolizumab in the crossover arm should be within  days of last dose but no less than  days from the last dose prior to crossing over
+Recent prior therapy, defined as follows: ) Any investigational or Food and Drug Administration (FDA)-approved anti-cancer drug within  days or  half-lives, whichever is longer, prior to the first dose of GSK. Any nitrosoureas or mitomycin C within  days prior to the first dose of GSK. Prior therapy with monoclonal antibodies is permitted so long as  days have elapsed since therapy and all therapy-related toxicity has resolved to Grade  or less. Note that an investigational drug is defined as a drug without an approved oncologic indication. ) Any radiotherapy within  days or major surgery within  days prior to the first dose of GSK. ) Anti-androgen therapies for prostate cancer, such as bicalutamide, must be stopped  weeks prior to enrollment. Second-line hormone therapies such as enzalutamide, abiraterone, or orteronel should be stopped  weeks prior to enrolment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone (up to  milligrams [mg]/day) and still be eligible for this study. ) In addition, any therapy-related toxicity must have resolved to Grade  or less, with the exception of alopecia (acceptable at any Grade) and peripheral neuropathy (which must be Grade  or less prior to enrollment).
+Patients may have had prior chemotherapy or immunotherapy or radiation therapy; all prior therapies must be stopped  weeks prior to first dose of study treatment, with the exception of patients who have received ipilimumab, which must be stopped  weeks prior to first dose of study treatment; patients are prohibited from receiving live vaccines within  days prior to first dose of study treatment
+Group C: progression following ceritinib is required and the last dose of ceritinib must be no more than  days prior to the first dose of study drug.
+Subjects must be neurologically stable for at least  days prior to first dose of study drug;
+Treatment with any investigational products within  days before the first dose of study drug and systemic anticancer therapy within  days before the first dose of study drug.
+Radioimmunotherapy within  weeks before first dose of study drug
+Participants must have had their last dose of cytotoxic chemotherapy at least  days prior to enrollment, their last dose of biological therapy, such as biological response modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating agents, used to treat their cancer at least  days prior to enrollment, their last dose of a monoclonal antibody at least  days prior to enrollment, and their last dose of any investigational agent at least  days prior to enrollment
+The patient has received maintenance dose chemotherapy (e.g., low dose cyclophosphamide) ?  days from the first dose of Investigational Product.
+Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames:
+Patient who has had chemotherapy, or biological cancer therapy within  weeks prior to the first dose of study drug; patient who has had radiation within  weeks prior to the first dose of study drug
+Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least  months after the last dose of atezolizumab,  months after the last dose of bevacizumab, or  month after the last dose of sorafenib
+Except for steroid refractory or intolerant cases, participants must be receiving baseline systemic glucocorticoid therapy for cGVHD at study entry; the dose of steroids must be stable for  days prior to starting study drug
+At the time of trial enrollment, participants may be receiving one or two other immunosuppressive therapies in addition to glucocorticoids; immunosuppressant doses must be stable for  days prior to starting study drug; monoclonal T or B cell antibodies must be discontinued at least  days before starting study drug
+Any prior therapy for castrate disease is acceptable except prior abiraterone, which is excluded; a minimum washout of  days for any other anticancer therapy prior to first dose of study drug is required\r\n* Any other radiotherapy or radionuclide require -day washout prior to first dose of study drug\r\n* Denosumab or zoledronic acid are allowed
+Plan to father a child while enrolled in this study or within  days after the last dose of study drug.
+Subject has received potent CYP A inhibitors within  days prior to first dose of study drug or proton pump inhibitors such as omeprazole within  days prior to first dose of study drug.
+Subject has any of the following within  days prior to the first dose of study drug:
+Subject has received the following within  days prior to the first dose of study drug:
+Subject has history of gastrointestinal ulcer within  days prior to the first dose of study drug.
+For the phase I portion of the study, patients who had received prior therapy with nilotinib should have been able to tolerate the dose equivalent to the starting dose of nilotinib in the dose level at which the patient is being entered; patients who previously received nilotinib but never at the dose being proposed are eligible provided they tolerated the maximum dose they were prescribed with no grade  or  toxicity not responding to optimal management
+Participated in another drug study within  days before this one
+. Received last dose of prior chemotherapy within ?  weeks of first dose of VS-.
+Anti-cancer therapy within  days prior to the first dose of study-drug treatment in Cycle 
+surgery, radiation, or immunosuppressants within  days prior to planned first dose of study drug,
+mitomycin-C or nitrosoureas within  days prior to planned first dose of study drug. Note: Patients receiving LHRH agonists or antagonists or antiestrogens or aromatase inhibitors started and at a stable dose for at least  days prior to planned first dose of study drug are eligible. Patients are permitted one  day cycle of concurrent treatment with hydroxyurea during the study.
+Prior hormone therapy is allowed, but last dose must be at least  days prior to first dose of MEDI.
+Subject has had any of the following within  days prior to the first dose of study drug:
+Treatment within  days prior to Dose  with:
+Any of the following clinical laboratory results during screening (i.e., within  days before the first dose of either study drug):
+High-dose chemotherapy within  weeks of study drug
+Systemic antineoplastic therapy within  days before the first dose of study drug
+Subject has received aspirin or warfarin within  days prior to the first dose of study drug
+WCBP must agree to have pregnancy tests monthly (every  days for women with irregular cycles) while on study drug and  weeks after the last dose of study drug
+Participants who have stopped study drug dosing for greater than  days
+Participants who have received any of the following within the listed time frame, prior to the first dose of study drug
+Participants who have received the following within  days prior to the first dose of study drug:
+Radiation therapy within  days of the first dose of study drug
+Subject has received a prior EGFR inhibitor within  days prior to the first dose of study drug.
+Subject has had any of the following within  days prior to the first dose of study drug:
+Prior anti-cancer therapy within  days before the first dose of study drug
+Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through  days after the last dose of talazoparib.
+At least  days since the last chemotherapy or immunotherapy prior to the first dose; at least  days since the last radiation prior to the first dose (exception: palliative radiotherapy for pain can be used greater than or equal to (>=)  days prior to or after infusion)
+The patient has been treated with radio- or toxin-immunoconjugates within  days of the first dose of the study drug
+For patients on higher than physiological level of corticosteroids, they must have been on a stable dose for  week prior to initiating study drug, and the dose should not be escalated over entry dose level, if clinically possible
+First dose of study medication must be greater than  days from completion of cytotoxic and antibody therapy and less than  days from previous therapy
+Systemic anti-tumor therapy within  days, or plasmapheresis within  days prior to the first dose of study drug
+Surgical intervention within  days prior to the first dose of M administration
+CLL therapy, with the exception of ibrutinib within the following timeframes:\r\n* Chemotherapy, external beam radiation therapy, anticancer antibodies within  days prior to the first dose of drug on this study\r\n* Corticosteroid use >=  mg prednisone within  week prior to first dose on this study\r\n* Radio- or toxin-conjugated antibody therapy within  weeks prior to first dose on this study\r\n* Allogeneic stem cell transplant within  months prior to first dose on this study